The LIRA-HF trial: liraglutide in heart failure with reduced ejection fraction and obesity – a 30-month randomized trial
GLP-1 receptor agonists reduce cardiovascular events in type 2 diabetes, but their role in heart failure with reduced ejection fraction (HFrEF) remains controversial due to concerns over heart rate elevation and potential arrhythmogenicity observed in prior trials. To evaluate whether liraglutide added to...